Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center
| Autor: | Serdar Sahin, Mehmet Cem Fidan, Pinar Kadioglu, Emre Durcan, Hande Mefkure Ozkaya, Ozge Polat Korkmaz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Cabergoline Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Gastroenterology Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Outcome Assessment Health Care Acromegaly Internal Medicine medicine Humans In patient Retrospective Studies medicine.diagnostic_test Tumor size business.industry Significant difference Magnetic resonance imaging Retrospective cohort study General Medicine Middle Aged medicine.disease Somatostatin Dopamine Agonists Drug Therapy Combination Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 129:644-650 |
| ISSN: | 1439-3646 0947-7349 |
| Popis: | Purpose To evaluate the effectiveness of cabergoline and the parameters affecting cabergoline response as add-on treatment to somatostatin analaogues (SSA) in patients with acromegaly uncontrolled with SSAs. Material and Method One hundred and twenty-nine acromegalic patients uncontrolled with SSA who had cabergoline added to their treatment were included in this retrospective study. Patients were divided into the SSAs + cabergoline-responsive (group 1) and non-responsive groups (group 2), and biochemical, pathologic, and radiologic parameters were assessed. Results IGF-1 normalization was achieved in 75 of 129 patients (58%) when cabergoline was added to the SSA treatment. Female patients were significantly higher in group 1 compared to group 2 (p=0.006). Group 1 had significantly smaller pre- and post-cabergoline tumor size (p=0.011, p=0.007 respectively), lower levels of IGF-1 in pre-and post-operative period (p=0.040, p=0.001), and lower levels of IGF-1 in pre- and post-cabergoline treatment (p Conclusion Cabergoline can be added to the treatment of acromegalic patients uncontrolled with SSAs due to its ease of use and low economic cost, especially in patients with acromegaly who have small adenomas and no fibrous bodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|